

# Juthathip Mongkolsapaya

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8816587/juthathip-mongkolsapaya-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73  
papers

8,834  
citations

39  
h-index

91  
g-index

91  
ext. papers

12,957  
ext. citations

22.6  
avg, IF

5.77  
L-index

#	Paper	IF	Citations
73	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.. <i>Cell</i> , <b>2022</b> ,	56.2	154
72	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.. <i>Lancet, The</i> , <b>2022</b> ,	40	46
71	Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.. <i>Nature Medicine</i> , <b>2022</b> ,	50.5	11
70	Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.. <i>Journal of Infectious Diseases</i> , <b>2022</b> ,	7	7
69	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies.. <i>EBioMedicine</i> , <b>2022</b> , 77, 103902	8.8	5
68	Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.. <i>Lancet, The</i> , <b>2021</b> ,	40	115
67	Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. <b>2021</b> ,		25
66	The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants.. <i>Cell Host and Microbe</i> , <b>2021</b> ,	23.4	14
65	The epitope arrangement on flavivirus particles contributes to Mab C10T's extraordinary neutralization breadth across Zika and dengue viruses. <i>Cell</i> , <b>2021</b> , 184, 6052-6066.e18	56.2	5
64	An immunodominant NP-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. <i>Nature Immunology</i> , <b>2021</b> ,	19.1	19
63	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. <i>Cell</i> , <b>2021</b> , 184, 5699-5714.e11	56.2	64
62	Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. <i>Nature Communications</i> , <b>2021</b> , 12, 6250	17.4	13
61	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. <i>Nature Communications</i> , <b>2021</b> , 12, 1951	17.4	25
60	Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. <i>ACS Central Science</i> , <b>2021</b> , 7, 594-602	16.8	47
59	The antigenic anatomy of SARS-CoV-2 receptor binding domain. <i>Cell</i> , <b>2021</b> , 184, 2183-2200.e22	56.2	145
58	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. <i>Cell</i> , <b>2021</b> , 184, 2348-2361.e6	56.2	549
57	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. <i>Cell</i> , <b>2021</b> , 184, 2201-2211.e7	56.2	269

56	Antibody evasion by the P.1 strain of SARS-CoV-2. <i>Cell</i> , <b>2021</b> , 184, 2939-2954.e9	56.2	281
55	Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. <i>Transfusion Medicine</i> , <b>2021</b> , 31, 167-175	1.3	42
54	Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine <b>2021</b> ,		13
53	Flavivirus maturation leads to the formation of an occupied lipid pocket in the surface glycoproteins. <i>Nature Communications</i> , <b>2021</b> , 12, 1238	17.4	12
52	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , <b>2021</b> , 184, 4220-4236.e16	42.6	136
51	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , <b>2021</b> , 398, 981-990	4.0	68
50	Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines. <i>Vaccines</i> , <b>2020</b> , 8,	5.3	8
49	Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. <i>Cell Host and Microbe</i> , <b>2020</b> , 28, 445-454.e6	23.4	187
48	Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. <i>Wellcome Open Research</i> , <b>2020</b> , 5, 139	4.8	120
47	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , <b>2020</b> , 5, 181	4.8	38
46	Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. <i>Eurosurveillance</i> , <b>2020</b> , 25,	19.8	36
45	Antibodies targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during pregnancy. <i>Nature Communications</i> , <b>2020</b> , 11, 5278	17.4	16
44	Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. <i>Nature Structural and Molecular Biology</i> , <b>2020</b> , 27, 950-958	17.6	175
43	Broad and strong memory CD4 and CD8 T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. <i>Nature Immunology</i> , <b>2020</b> , 21, 1336-1345	19.1	615
42	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. <i>Lancet Infectious Diseases, The</i> , <b>2020</b> , 20, 1390-1400	25.5	212
41	Autoantibody-dependent amplification of inflammation in SLE. <i>Cell Death and Disease</i> , <b>2020</b> , 11, 729	9.8	9
40	A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection. <i>Nature Immunology</i> , <b>2019</b> , 20, 1291-1298	19.1	33
39	Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice. <i>Cell Reports</i> , <b>2019</b> , 26, 1585-1597.e4	10.6	9

38	Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 536-545	7	95
37	Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Challenges of a Dengue Vaccine. <i>Cold Spring Harbor Perspectives in Biology</i> , <b>2018</b> , 10,	10.2	12
36	Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. <i>Nature Medicine</i> , <b>2018</b> , 24, 721-723	50.5	35
35	Neutrophil Activation and Early Features of NET Formation Are Associated With Dengue Virus Infection in Human. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 3007	8.4	28
34	The immunology of Zika Virus. <i>F1000Research</i> , <b>2018</b> , 7, 203	3.6	15
33	Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus. <i>Nature Immunology</i> , <b>2018</b> , 19, 1248-1256	19.1	21
32	The immune response against flaviviruses. <i>Nature Immunology</i> , <b>2018</b> , 19, 1189-1198	19.1	82
31	Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	15
30	Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. <i>Nature Communications</i> , <b>2018</b> , 9, 2441	17.4	51
29	Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope. <i>Nature Communications</i> , <b>2017</b> , 8, 15411	17.4	48
28	Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection. <i>Nature Immunology</i> , <b>2017</b> , 18, 1261-1269	19.1	74
27	Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8 T cell response. <i>Nature Immunology</i> , <b>2017</b> , 18, 1228-1237	19.1	22
26	The immunopathology of dengue and Zika virus infections. <i>Current Opinion in Immunology</i> , <b>2017</b> , 48, 1-6	7.8	22
25	Evolution of neurovirulent Zika virus. <i>Science</i> , <b>2017</b> , 358, 863-864	33.3	6
24	MAIT cells are activated during human viral infections. <i>Nature Communications</i> , <b>2016</b> , 7, 11653	17.4	283
23	Structural basis of potent Zika-dengue virus antibody cross-neutralization. <i>Nature</i> , <b>2016</b> , 536, 48-53	50.4	362
22	Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. <i>Nature Immunology</i> , <b>2016</b> , 17, 1102-8	19.1	637
21	Recent advances in understanding dengue. <i>F1000Research</i> , <b>2016</b> , 5,	3.6	31

20	Antibodies and tuberculosis. <i>Tuberculosis</i> , <b>2016</b> , 101, 102-113	2.6	93
19	New insights into the immunopathology and control of dengue virus infection. <i>Nature Reviews Immunology</i> , <b>2015</b> , 15, 745-59	36.5	212
18	A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. <i>Nature Immunology</i> , <b>2015</b> , 16, 170-177	19.1	309
17	Recognition determinants of broadly neutralizing human antibodies against dengue viruses. <i>Nature</i> , <b>2015</b> , 520, 109-13	50.4	234
16	Sensing of immature particles produced by dengue virus infected cells induces an antiviral response by plasmacytoid dendritic cells. <i>PLoS Pathogens</i> , <b>2014</b> , 10, e1004434	7.6	43
15	Invariant NKT cell response to dengue virus infection in human. <i>PLoS Neglected Tropical Diseases</i> , <b>2014</b> , 8, e2955	4.8	16
14	A simplified positive-sense-RNA virus construction approach that enhances analysis throughput. <i>Journal of Virology</i> , <b>2013</b> , 87, 12667-74	6.6	34
13	Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity. <i>Journal of Immunology</i> , <b>2012</b> , 188, 4971-9	5.3	65
12	An in-depth analysis of original antigenic sin in dengue virus infection. <i>Journal of Virology</i> , <b>2011</b> , 85, 410-416	14.6	145
11	Cross-reacting antibodies enhance dengue virus infection in humans. <i>Science</i> , <b>2010</b> , 328, 745-8	33.3	624
10	T cell responses to whole SARS coronavirus in humans. <i>Journal of Immunology</i> , <b>2008</b> , 181, 5490-500	5.3	344
9	T cell Responses and Dengue Haemorrhagic Fever. <i>Novartis Foundation Symposium</i> , <b>2008</b> , 164-176		11
8	T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal?. <i>Journal of Immunology</i> , <b>2006</b> , 176, 3821-9	5.3	210
7	Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. <i>Nature Medicine</i> , <b>2003</b> , 9, 921-7	50.5	609
6	Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. <i>Nature Structural Biology</i> , <b>1999</b> , 6, 1048-53		214
5	A high resolution view of an adolescent flavivirus		2
4	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2		6
3	Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2		14

2	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 Beta (B.1.351) and other variants of concern in preclinical studies	8
1	Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum	3